Vienna (Austria)/Gaithersburg (USA), July 2, 2010 - Intercell AG (VSE: ICLL) today announced the results of a Phase II clinical trial of its investigational Vaccine Enhancement Patch (VEP) system for ...
Intercell is planning to acquire the needle-free immunization developer, Iomai , for $189.0 million, or $6.60 a share, in hopes of becoming the international traveler's best friend with a new ...
LONDON/PARIS (Reuters) - France's Vivalis and Austrian vaccine specialist Intercell are linking up in a rare cross-border deal that shows the need for Europe's fledgling biotech companies to grow in ...
ZURICH (Reuters) - U.S. drugmaker Merck & Co <MRK.N> is to discontinue a major trial of a key vaccine from Intercell <ICEL.VI> designed to protect against serious hospital infections, the Austrian ...
Austrian vaccine maker Intercell has revealed interim results from a Phase II study for its hepatitis C vaccine showed a significant viral load reduction and good safety profile. Austrian vaccine ...
VIENNA, Austria, Aug. 28 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that its collaborator Merck & Co., Inc. has initiated a Phase II clinical trial of V710, an investigational vaccine ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Intercell jumped 16 per cent after the Austrian biotechnology company announced that it had agreed a ...
Wolfgang Renner, CEO of Cytos, commented: "Intercell, as a leading anti-infective company, is ideally positioned through its Antigen Identification Program (AIP®), to capture the full value of our ...
Initiation of a first-in-man Phase I clinical trial in healthy subjects Study aims to obtain safety and immunogenicity data of this new vaccine candidate Initial results expected in Q4 2009 ...
Intercell AG has announced that the company’s Supervisory Board has appointed Thomas Lingelbach as new Chief Executive Officer (CEO) for Intercell, effective May 10, 2011. At the same time, Gerd ...
DALLAS--(BUSINESS WIRE)--Aug. 18, 2006--NewMarket Technology Maintains 60% Ownership in Intercell with Dilution Protection and Continued Consolidation of Subsidiary Results of Operations NewMarket ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results